Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | DDT | P30046 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | BLVRB | P30043 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | CD74 | P04233 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | VCP | P55072 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19982693 | 0.83 | KAT6A (0.48) | KMOKEAP1KAT6AL3MBTL1NPC1 | |
| SCHEMBL29045125 | 0.81 | NPC1 (0.52) | KAT6ANPC1RAB9AALDH1A1 | |
| SCHEMBL15515155 | 0.79 | TP53 (0.46) | NPC1RAB9AKDM4EALDH1A1RXRA | |
| SCHEMBL17984217 | 0.79 | GP6 (0.44) | KMOKAT6AL3MBTL1NPC1RAB9A | |
| SCHEMBL940696 | 0.77 | KMO (0.62) | KMOKEAP1KAT6AL3MBTL1NPC1 | |
| SCHEMBL30516097 | 0.77 | MKNK1 (0.47) | KMOKDM4EALDH1A1POLB | |
| SCHEMBL28069322 | 0.76 | KMO (0.67) | KMOKEAP1L3MBTL1NPC1RAB9A | |
| SCHEMBL31734205 | 0.76 | KMO (0.67) | KMOKEAP1L3MBTL1NPC1RAB9A | |
| SCHEMBL14027290 | 0.76 | MGLL (0.58) | NPC1RAB9AKDM4EALDH1A1POLB | |
| SCHEMBL30207 | 0.76 | PPARA (0.46) | KMOKAT6AL3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4101846-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116514790-A | Tri-aromatic heterocyclic piperazine small molecular organic compound targeting STAT3 and application thereof | 华东师范大学 | 2023-08-01 | — | — | CN | disclosed |
| EP-4101846-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| CN-114920667-A | Electrochemical preparation method of astraglucol | 湖南大学 | 2022-08-19 | — | — | CN | disclosed |
| EP-3889142-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20220071967-A1 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME | CIPOLLI MARLO (IT) | 2022-03-10 | — | — | US | disclosed |
| US-11207300-B2 | Method of treatment of Shwachman-diamond syndrome | Cipolli, Marco | 2021-12-28 | — | — | US | disclosed |
| EP-3889142-A1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3632902-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3549936-B1 | 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUND AND ITS USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS INC (US) | 2021-06-02 | — | — | EP | disclosed |
| US-8008290-B2 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2011-08-30 | — | — | US | disclosed |
| US-7960562-B2 | Propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| EP-2297162-A1 | COMPOUNDS | Amura Therapeutics Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2283022-A1 | FURO Ý3, 2-B¨PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | Amura Therapeutics Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20110009385-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| WO-2009112826-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112839-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| EP-1864976-A1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071967-A1 | METHOD OF TREATMENT OF SHWACHMAN-DIAMOND SYNDROME | DKC1, SAMHD1, RRM2B | KMO 3367/4885KEAP1 1025/4885KAT6A 2514/4885 |
| US-11207300-B2 | Method of treatment of Shwachman-diamond syndrome | DKC1, SAMHD1, RRM2B | KMO 3367/4885KEAP1 1025/4885KAT6A 2514/4885 |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GNRHR, KISS1R, FSHR | KMO 907/4885KEAP1 2431/4885KAT6A 3899/4885 |
| US-20110009385-A1 | COMPOUNDS | CTSK, CTSS, MMP9 | KMO 2550/4885KEAP1 1675/4885KAT6A 659/4885 |
| US-20110009386-A1 | FURO[3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | KMO 495/4885KEAP1 3543/4885KAT6A 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.